| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| clazakizumab | interleukin-6 | NA | Successful target | TTD , DGIDB | Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
7.64 | phase 2 | inhibitor |
| clazakizumab | interleukin-6 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Crohn Disease[MeSHID:D003424] Rheumatoid Arthritis[MeSHID:D001172] |
7.64 | phase 2 | unknown |
| clazakizumab | interleukin-6 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Crohn Disease[MeSHID:D003424] Rheumatoid Arthritis[MeSHID:D001172] |
7.64 | phase 2 | inhibitor |
| clazakizumab | interleukin-6 | NA | Successful target | TTD , DGIDB | Disease[MeSHID:D004194] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
7.64 | phase 2 | unknown |
| click here to return to the previous page | ||||||||